Quarterly ResultAug 6, 2026, 07:02 AM
Climb Bio Extends Cash Runway to H2 2028; Advances Clinical Pipeline
AI Summary
Climb Bio reported its second quarter 2026 financial results and provided significant business updates, highlighting a strong pipeline progression. The company extended its cash runway into the second half of 2028, supported by a recent $110 million private placement. Key clinical milestones include the anticipated initiation of the CLYM116 Phase 2 trial in IgA nephropathy in Q3 2026 and multiple data readouts for budoprutug programs in Q4 2026.
Key Highlights
- Cash runway extended into H2 2028 following a $110 million private placement.
- CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026.
- Budoprutug clinical data from pMN, ITP, and SLE studies expected in Q4 2026.
- Q2 2026 R&D expenses were $9.7 million, up from $6.6 million in Q2 2025.
- Q2 2026 G&A expenses were $5.6 million, up from $4.1 million in Q2 2025.
- Net loss for Q2 2026 was $13.5 million, compared to $8.7 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $239.2 million as of June 30, 2026.
Price Impact
More from CLYM